Close Menu

NEW YORK (GenomeWeb) – Rosetta Genomics said today that it has entered into a definitive agreement with an institutional healthcare investor for a $2 million private placement.

Under the terms of the agreement, Rosetta will issue unregistered convertible debentures (convertible into approximately 2.2 million ordinary shares) and warrants to purchase up to the same number of ordinary shares for gross proceeds of $2 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.